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Résumé en
anglais
Recently developed drug delivery nanosystems, such as lipid nanocapsules (LNCs),
hold great promise for the treatment of glioblastomas (GBs). In this study, we used
a subpopulation of human mesenchymal stem cells, "marrow-isolated adult
multilineage inducible" (MIAMI) cells, which have endogenous tumor-homing
activity, to deliver LNCs containing an organometallic complex (ferrociphenol or Fc-
diOH), in the orthotopic U87MG GB model. We determined the optimal dose of Fc-
diOH-LNCs that can be carried by MIAMI cells and compared the efficacy of Fc-
diOH-LNC-loaded MIAMI cells with that of the free-standing Fc-diOH-LNC system.
We showed that MIAMI cells entrapped an optimal dose of about 20 pg Fc-diOH per
cell, with no effect on cell viability or migration capacity. The survival of U87MG-
bearing mice was longer after the intratumoral injection of Fc-diOH-LNC-loaded
MIAMI cells than after the injection of Fc-diOH-LNCs alone. The greater effect of
the Fc-diOH-LNC-loaded MIAMI cells may be accounted for by their peritumoral
distribution and a longer residence time of the drug within the tumor. These results
confirm the potential of combinations of stem cell therapy and nanotechnology to
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